Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Multiple Sclerosis l: Introduction01:19

Multiple Sclerosis l: Introduction

Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Myasthenia Gravis: Diagnostic Tests01:15

Myasthenia Gravis: Diagnostic Tests

Myasthenia gravis is an autoimmune condition affecting neuromuscular transmission, causing generalized weakness in skeletal muscles. Initial diagnoses rely on patients' signs, symptoms, and medical history. The challenge lies in distinguishing myasthenia from other muscular dystrophies. An important diagnostic feature is the significant improvement of symptoms after administering anticholinesterase inhibitors.
The edrophonium test is a diagnostic tool for myasthenia gravis. It involves...
Parkinson Disease ll: Pathophysiology01:24

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Noradrenergic Brain in Parkinson's Disease.

Current neurology and neuroscience reports·2026
Same author

Essential Tremor and Digital Biomarkers: A Scoping Review Using the TRACE Framework to Map Readiness for Clinical Trials and Routine Practice.

Tremor and other hyperkinetic movements (New York, N.Y.)·2026
Same author

Novel Variants in PUS7 Associated With Intellectual Disability and Growth Retardation: Expanding the Clinical Spectrum in 13 Patients.

Clinical genetics·2026
Same author

COXFA4L2 upregulation preserves residual cytochrome c oxidase activity in COXFA4-related Leigh-like encephalopathy.

Nature communications·2026
Same author

Observations on an Open-Label Phase 1/2 Dopamine Gene Therapy Trial (OXB-102/Axo-Lenti-PD) in People with Parkinson's Disease.

Movement disorders : official journal of the Movement Disorder Society·2026
Same author

Progressive Supranuclear Palsy in India: Insights from a Large Multicenter Clinical Cohort (Project PAIR-PSP).

Movement disorders clinical practice·2026
Same journal

Multiple spinal muscular atrophy disease-modifying effects of a Hspa8G470R synaptic chaperone variant.

Brain : a journal of neurology·2026
Same journal

STMN2 protein depletion via translation deficits and stress granules in amyotrophic lateral sclerosis.

Brain : a journal of neurology·2026
Same journal

Reply: Cerebrovascular contributions to the 'vulnerable' medial temporal lobe T-N phenotype.

Brain : a journal of neurology·2026
Same journal

Identification of a central CGRP circuit for trigeminal V1-mediated migraine-like pain in mice.

Brain : a journal of neurology·2026
Same journal

Cerebrovascular contributions to the 'vulnerable' medial temporal lobe T-N phenotype.

Brain : a journal of neurology·2026
Same journal

Combining post-mortem and neuroimaging measures of brain amyloidosis to accelerate genomic discovery.

Brain : a journal of neurology·2026
See all related articles
  1. Home
  3. Clinical Prognostic Indicators In Multiple System Atrophy.
  1. Home
  3. Clinical Prognostic Indicators In Multiple System Atrophy.

Related Experiment Video

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Clinical prognostic indicators in multiple system atrophy.

Yee Yen Goh1, Viorica Chelban1, Nirosen Vijiaratnam2

  • 1Department of Neuromuscular Diseases, UCL Queen Square Institute of Neurology, UCL, Queen Square, London, WC1N 3BG, UK.

Brain : a Journal of Neurology
|May 7, 2026

View abstract on PubMed

Summary
This summary is machine-generated.

This study identifies key factors for predicting survival in Multiple System Atrophy (MSA) patients, revealing that clinical milestones and rating scales aid prognostication. Understanding these time-dependent factors improves patient care and clinical trial design for MSA.

Keywords:
dysautonomianeurodegenerationparkinsonismprognosisprogressionsurvival

More Related Videos

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

Related Experiment Videos

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool
11:35

The Multiple Sclerosis Performance Test (MSPT): An iPad-Based Disability Assessment Tool

Published on: June 30, 2014

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis
08:16

Utility of Dissociated Intrinsic Hand Muscle Atrophy in the Diagnosis of Amyotrophic Lateral Sclerosis

Published on: March 4, 2014

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

Area of Science:

  • Neurology
  • Neurodegenerative Diseases
  • Clinical Prognostics

Background:

  • Multiple System Atrophy (MSA) is a rare neurodegenerative disorder with variable survival rates (6-10 years typically), complicating patient management and clinical trial stratification.
  • Previous prognostication studies in MSA have yielded conflicting results, potentially due to diagnostic inaccuracies and limited sample sizes.
  • Accurate prediction of MSA progression is crucial for patient care, resource allocation, and designing effective therapeutic trials.

Purpose of the Study:

  • To identify and validate survival prognostic factors in a large cohort of Multiple System Atrophy (MSA) patients.
  • To investigate the time-dependent nature of prognostic factors in MSA.
  • To improve clinical trial stratification and patient care through enhanced MSA prognostication.

Main Methods:

  • Survival analysis was conducted on a combined cohort of 555 MSA patients from the Queen Square Brain Bank and the PROSPECT-M-UK study.
  • Methods included counting process Cox proportionate hazards modelling, Kaplan-Meier log-rank testing, and landmark survival analysis to address guarantee-time bias.
  • Clinical data, including disease onset, specific MSA subtypes (MSA-P, MSA-C, mixed), clinical milestones (wheelchair use, gastrostomy, speech intelligibility), and Unified Multiple System Atrophy Rating Scale (UMSARS) scores, were analyzed.

Main Results:

  • Later disease onset was associated with shorter survival (HR=1.04, P<0.001).
  • Key late-stage disease markers with median survival <1.5 years included indoor wheelchair use, gastrostomy insertion, and unintelligible speech.
  • At 3 years post-onset, negative prognostic factors included recurrent falls, unintelligible speech, and catheter/orthostatic hypotension medication use (all P<0.05). At 5 years, mobility milestones became more significant than dysautonomia markers.
  • Higher baseline UMSARS scores and faster UMSARS progression rates were significant negative prognostic factors (HR=1.03 and 1.07, P<0.001).

Conclusions:

  • In-clinic rating scales and clinical milestone assessments are valuable tools for aiding Multiple System Atrophy (MSA) prognostication.
  • Prognostic factors in MSA exhibit time-dependent variability, explaining heterogeneity in previous studies and highlighting the need for dynamic assessment.
  • This improved understanding of MSA prognostication is vital for personalized patient care and for the rational stratification of patients in future clinical trials.